Company Overview of Sabin Vaccine Institute
1889 F Street, N.W
Washington, DC 20006-4400
Founded in 2007
Key Executives for Sabin Vaccine Institute
Compensation as of Fiscal Year 2016.
Sabin Vaccine Institute Key Developments
Sabin Vaccine Institute Announces Management Changes
Mar 24 16
The Sabin Vaccine Institute announced the appointment of Amy Finan as its next chief executive officer. Finan, currently the senior vice president responsible for business development with the Biotechnology Innovation Organization, will assume her new role with Sabin on April 18, 2016.
During her 11-year tenure with BIO, Finan played a critical role in expanding the organization's membership and revenue base and implementing forward-leaning approaches to fundraising, branding, marketing and programming. In 2011 and simultaneous with her BIO responsibilities, she also served as president of the s Biotechnology Institute, an organization founded by BIO in 1998 to promote life science education. Finan succeeds Michael W. Marine, who will retire on April 15, 2016.
Sabin Vaccine Institute Announces Board Changes
Dec 10 14
The Sabin Vaccine Institute announced that its board of trustees unanimously appointed Axel Hoos, MD, PhD, to serve as the interim chairman of the board. Building upon the past successes of late chairman Morton P. Hyman, Dr. Hoos will be instrumental to providing continuity to the institute and to Sabin's efforts in launching new programs, clinical trials and advocacy campaigns around the world. Dr. Hoos has been a member of Sabin's Board of Trustees since 2006, providing valuable guidance during a period of tremendous growth in the scope and reach of the organization. Currently, Dr. Hoos is vice president, GlaxoSmithKline, where he is responsible for building GSK's Immuno-Oncology portfolio.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries